LyondellBasell (LYB)
NYSEMaterialsChemicals - SpecialtySnapshot 2026-10-30
$68.64+5.00%
Close 2026-10-30 · 1-day change
NYSEMaterialsChemicals - SpecialtySnapshot 2026-10-30
Research Workspace
Put LYB beside peers and holdings, graph the same metric, and keep your notes with the evidence.
Daily closes. Earnings/event dots are placed inline.
Industries move in repeating boom-and-bust cycles. This shows where this stock’s industry sits in that cycle, stage by stage (recovery → expansion → supercycle → steady → deceleration → contraction), from its fundamentals (orders, revenue, capital spending), not the stock’s price.
A booming industry is a tailwind for the names in it; a contracting one is a headwind. Companies in the same industry tend to rise and fall together with the cycle, the way a tide lifts and lowers every boat in the harbor at once, so a large part of a stock’s swing can come from where its industry sits rather than from the company itself. It’s context for reading the company’s results, not a buy/sell call. Full explanation →
Specialty Chemicals is in recovery. Describes the industry's cycle state, not a call on this stock.
The stage band shows the industry’s cycle over the chart’s timeline (each color a stage); a ▼ marks a quarter its growth inflected down — amber is an unconfirmed watch, red is confirmed the next quarter. Use “Overlay cycle on chart” to tint the price chart by stage. The industry’s fundamentals, not a signal on this stock.
Primary pillar under pressure — Revenue growth above 7% annually: Comparison needs review.
View ThesisRevenue is growing steadily — about 4% over the past year.
View GrowthRanks in the weakest quality tier of its industry — roughly the bottom 44%, softest on free-cash-flow margins.
View QualityManagement screens weak on earnings delivery, the balance sheet, market reaction to earnings.
View ManagementExpectations look reasonable — what the market is pricing in sits in line with or below what analysts forecast.
View ValuationThis stock is volatile — it swings about 1% on a typical day and fell roughly 36% in its worst 12-month stretch.
View RiskLYB’s thesis rests on portfolio transformation and steady recent financial performance, despite elevated risk. Revenue data is unavailable, and third-quarter 2026 non-GAAP earnings missed consensus by 7%. LYB trades at 10× P/E versus a 17× peer median. The price reflects less growth than our forecast, despite the latest earnings miss. We estimate a 28% next-quarter earnings miss probability. Fragile earnings quality means reported profits are not well backed by cash. Peer multiples imply a price about 8% above where it trades. The thesis is on watch, and this read is provisional.
Trailing returns as of 2026-10-30. LYB is total return (includes dividends); the S&P 500 benchmark is price return (the index excludes dividends).
Based on 22 analysts currently covering LYB (as of Oct 2026).
Based on 9 Wall Street analysts offering 12-month price targets for LYB in the last 4 months.
Continue this research
Compare LYB with peers and holdings, graph the same reported metric, keep your questions beside the evidence, and return when the facts change.
Compare now without an account. Saving and monitoring require an account.
| Compare | Company | Living FV | P/E | Revenue % | Quality |
|---|---|---|---|---|---|
| LYB Selected company | Graph | Compare | Trend | Review | |
| Peer Add a competitor | Graph | Compare | Trend | Review | |
| Holding Compare a holding | Graph | Compare | Trend | Review |
Selected metric trend
Quarterly · checked companies · value or % of revenue
A consensus fair price across 10 valuation methods, at three horizons. As of 2026-10-30. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
A price-focused, side-by-side fair-value read versus Specialty Chemicals — fair value, gap to price, and forward P/E.
Compare the value case
Put LYB next to peers and holdings, compare Living FV and multiples, then graph the driver behind the difference.
Advances: Portfolio transformation via divestiture of select European assets
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
End-of-day figures as of 2026-10-30. EPS is implied from price ÷ P/E. Not investment advice.
Current $68.64
The last 12 months of price, then the range of analyst 12-month targets from today’s $68.64.
Analyst ratings and price targets are third-party Wall Street estimates, not QuarterlyIQ’s view. Not investment advice.
A long-thesis check that carries the widest uncertainty of the three horizons.
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.
Refinery-site sale targets support European portfolio transformation and are expected to lift annual cash flow.
Q3 results missed estimates amid weaker demand, signaling near-term pressure on earnings and operating conditions.
Potential acquisition aligns with portfolio transformation objective.
Potential acquisition aligns with portfolio transformation objective.
Interest in Shell's assets supports growth strategy.
Advances: Cash Improvement Plan targeting $1.3B by end of 2026
Upgrade indicates confidence in cash improvement plan.
Advances: Cash Improvement Plan targeting $1.3B by end of 2026
Upgrade reflects confidence in cash improvement plan.
Advances: Cash Improvement Plan targeting $1.3B by end of 2026
EBITDA tripling supports cash improvement plan.
